Found: 21
Select item for more details and to access through your institution.
A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 4, p. 328, doi. 10.1002/cpdd.86
- By:
- Publication type:
- Article
A Novel Approach to Evaluate the Pharmacokinetic Biocomparability of a Monoclonal Antibody Derived from Two Different Cell Lines Using Simultaneous Crossover Design.
- Published in:
- AAPS Journal, 2014, v. 16, n. 1, p. 125, doi. 10.1208/s12248-013-9547-6
- By:
- Publication type:
- Article
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 669, doi. 10.1007/s10637-012-9857-z
- By:
- Publication type:
- Article
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 760, doi. 10.1007/s10637-012-9869-8
- By:
- Publication type:
- Article
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 6, p. 1395, doi. 10.1007/s10637-010-9484-5
- By:
- Publication type:
- Article
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 5, p. 445, doi. 10.1007/s10637-007-9050-y
- By:
- Publication type:
- Article
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
- Published in:
- Prostate, 2011, v. 71, n. 13, p. 1455, doi. 10.1002/pros.21362
- By:
- Publication type:
- Article
Dose selection of siltuximab for multicentric Castleman's disease.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 1037, doi. 10.1007/s00280-015-2720-0
- By:
- Publication type:
- Article
Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 1, p. 35, doi. 10.1007/s00280-013-2314-7
- By:
- Publication type:
- Article
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 1041, doi. 10.1007/s00280-013-2099-8
- By:
- Publication type:
- Article
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 6, p. 1165, doi. 10.1007/s00280-009-0979-8
- By:
- Publication type:
- Article
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 10, p. 1020, doi. 10.1002/jcph.140
- By:
- Publication type:
- Article
Pharmacodynamic Modeling of Lansoprazole Using an Indirect Irreversible Response Model.
- Published in:
- Journal of Clinical Pharmacology, 2001, v. 41, n. 3, p. 251, doi. 10.1177/009127000104100302
- By:
- Publication type:
- Article
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 1, p. 42, doi. 10.1002/ajh.23868
- By:
- Publication type:
- Article
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 6, p. 1345, doi. 10.1111/cts.12836
- By:
- Publication type:
- Article
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 111, doi. 10.1007/s11523-014-0320-2
- By:
- Publication type:
- Article